Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLC

NCT05668650 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

174

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Small Cell Lung Cancer Metastatic

Interventions

DRUG: Pembrolizumab
DRUG: Pembrolizumab biosimilar

Sponsor

Laboratorio Elea Phoenix S.A.

Collaborators

[object Object]